title: Clinical features and outcomes of nontransitional cell carcinomas of the urinary bladder: Analysis of 125 cases.
abstract: OBJECTIVE
  The aim was to evaluate pathologic diagnosis, treatment and prognosis of 125 patients with nontransitional cell carcinoma of the urinary bladder.
  
  
  METHODS
  A total of 3590 patients with bladder tumors operated in our clinic between September 1998 and May 2013 were retrospectively evaluated. A total of 125 patients (107 men and 18 women) with nontransitional cell bladder cancer, confirmed by histopathology, were included in this study. The patients' characteristics, including age, gender, smoking history, tumor size, and localization, histological types, pathological tumor stages, treatment modalities, and survival rates were all recorded.
  
  
  RESULTS
  Of these tumors, 47 (37.6%) were adenocarcinoma (AC), 42 (33.6%) were squamous cell carcinoma (SCC), 23 (18.4%) were undifferentiated carcinoma (UC), 13 (10.4%) were other types of bladder carcinoma. Sixty-three (50.4%) patients had undergone radical cystectomy and pelvic lymphadenectomy ± adjuvant treatment (chemotherapy [CT]/radiotherapy) and 52 (41.6%) patients received radiotherapy ± CT. The median survival time of patients with AC and SCC were significantly higher than patients with UC (AC vs UC, P = 0.001; SCC vs UC, P = 0.000; AC vs. SCC, P = 0.219). Median survival time was significantly higher in radical cystectomy ± adjuvant treatment group (P < 0.05) in all histological types.
  
  
  CONCLUSIONS
  Prognosis of urinary bladder tumors was directly related to histological type and stage of the tumor. CT or radiotherapy has limited response rates. Early radical cystectomy should be performed to improve prognosis.
authors.affiliation: Department of Urology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey.
authors.forename: Burak
authors.initials: B
authors.lastname: Arslan
authors.affiliation: Department of Urology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey.
authors.forename: Ibrahim Halil
authors.initials: IH
authors.lastname: Bozkurt
authors.affiliation: Department of Urology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey.
authors.forename: Tarik
authors.initials: T
authors.lastname: Yonguc
authors.affiliation: Department of Urology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey.
authors.forename: Enver
authors.initials: E
authors.lastname: Vardar
authors.affiliation: Department of Urology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey.
authors.forename: Tansu
authors.initials: T
authors.lastname: Degirmenci
authors.affiliation: Department of Urology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey.
authors.forename: Zafer
authors.initials: Z
authors.lastname: Kozacioglu
authors.affiliation: Department of Urology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey.
authors.forename: Bulent
authors.initials: B
authors.lastname: Gunlusoy
authors.affiliation: Department of Urology, Izmir Bozyaka Training and Research Hospital, Bozyaka, Izmir, Turkey.
authors.forename: Suleyman
authors.initials: S
authors.lastname: Minareci
keywords: Adenocarcinoma; cystectomy; squamous cell carcinoma
references.citation: Expert Rev Anticancer Ther. 2012 Dec;12(12):1499-502
references.pmid: 23253215
references.citation: Onco Targets Ther. 2013 Aug 26;6:1179-85
references.pmid: 24009428
references.citation: Cancer. 1983 Oct 1;52(7):1273-80
references.pmid: 6883290
references.citation: Br J Urol. 1982 Oct;54(5):522-6
references.pmid: 7171960
references.citation: Urology. 2007 Feb;69(2):255-9
references.pmid: 17320659
references.citation: Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):8-18
references.pmid: 17536302
references.citation: Int J Clin Oncol. 2005 Feb;10(1):20-5
references.pmid: 15729596
references.citation: Int J Cancer. 1999 Jan 5;80(1):44-6
references.pmid: 9935228
references.citation: J Urol. 1976 May;115(5):542-4
references.pmid: 1271546
references.citation: Diagn Pathol. 2012 Nov 02;7:151
references.pmid: 23121893
references.citation: Eur Urol. 2000 Jan;37(1):85-9
references.pmid: 10671791
references.citation: Arch Pathol Lab Med. 2000 Mar;124(3):455-9
references.pmid: 10705407
references.citation: Hum Pathol. 2009 Jan;40(1):108-16
references.pmid: 18789486
references.citation: BJU Int. 2005 Mar;95(4):497-502
references.pmid: 15705067
references.citation: Br J Urol. 1998 Aug;82(2):206-12
references.pmid: 9722755
references.citation: Mod Pathol. 2006 Nov;19(11):1395-401
references.pmid: 16951671
references.citation: Int J Cancer. 2013 Mar 1;132(5):1133-45
references.pmid: 22752881
references.citation: J Urol. 1997 Aug;158(2):393-9
references.pmid: 9224310
references.citation: Cancer. 1991 Apr 15;67(8):2165-72
references.pmid: 1706216
references.citation: Int J Urol. 2003 Oct;10(10):525-9
references.pmid: 14516399
references.citation: BJU Int. 2004 Jan;93(2):216-20
references.pmid: 14690486
references.citation: Sarcoma. 2010;2010:null
references.pmid: 20706685
references.citation: J Urol. 1998 May;159(5):1497-503
references.pmid: 9554341
references.citation: Cancer. 1981 Dec 15;48(12):2643-8
references.pmid: 7306921